Tissue/site-agnostic study of ribociclib for tumors with cyclin D-CDK4/6 pathway genomic alterations: A Phase II, open-label, single-arm basket study

Julio Peguero, Davendra P.S. Sohal, Bert H. O'Neil, Howard Safran, Karen Kelly, Juneko E. Grilley-Olson, Vivek Subbiah, Lincoln Nadauld, Das Purkayastha, Erica Stealey, Alejandro D. Ricart, Barinder P. Kang, Joseph Paul Eder

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

PURPOSE As part of the Novartis Signature Program, this study evaluated the efficacy of ribociclib (selective cyclin-dependent kinase 4/6 [CDK4/6] inhibitor) in patients with cyclin D-CDK4/6 pathway-aberrant tumors. METHODS This was a phase II, single-arm, signal-seeking study in patients with advanced malignancies that had progressed on or after standard treatment. Prior identification of tumor CDK4/6 mutation or amplification, CCND1/3 amplification, or CDKN2A mutation or loss was required. Clinical benefit (defined as the proportion of patients with response or stable disease at ≥ 16 weeks) was the primary end point. RESULTS From 61 centers in the United States, 106 patients (median age, 62.5 years) were enrolled across multiple malignancies. The patient population was heavily pretreated (median number of prior therapies, three; range, 0 to 19). Median progression-free survival was 1.8 months (95% CI, 1.8 to 1.9). In patients with solid tumors, the clinical benefit rate was 18.1% (n = 19 of 105) and the overall response rate was 2.9% (n = 3 of 105); three partial responses occurred in patients with adenocarcinoma (unknown primary), soft tissue sarcoma, and urothelial carcinoma. No tumor cohort met the prespecified criteria for success. The most common adverse events suspected to be related to treatment were neutropenia (30.2%; decreased neutrophils, 15.1%), fatigue (31.1%), and nausea (29.2%). Fatigue and nausea were typically mild. Only one incident of febrile neutropenia was experienced (grade 3). CONCLUSION No new or unexpected safety signals were observed in this heavily pretreated patient population. Although responses were seen in tumors with CCND1-CDK4/6 amplifications, the primary end point was not met, suggesting additional evaluation of ribociclib, possibly as combination therapy, is needed.

Original languageEnglish (US)
JournalJCO Precision Oncology
Volume2
DOIs
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Tissue/site-agnostic study of ribociclib for tumors with cyclin D-CDK4/6 pathway genomic alterations: A Phase II, open-label, single-arm basket study'. Together they form a unique fingerprint.

  • Cite this

    Peguero, J., Sohal, D. P. S., O'Neil, B. H., Safran, H., Kelly, K., Grilley-Olson, J. E., Subbiah, V., Nadauld, L., Purkayastha, D., Stealey, E., Ricart, A. D., Kang, B. P., & Eder, J. P. (2018). Tissue/site-agnostic study of ribociclib for tumors with cyclin D-CDK4/6 pathway genomic alterations: A Phase II, open-label, single-arm basket study. JCO Precision Oncology, 2. https://doi.org/10.1200/PO.18.00383